CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: To prove that Tregs in the BM constrain antileukemic CD8+ T cell immunity in CML, Foxp3DTR CML mice were treated 13 days after CML induction with either PBS, DT, or a depleting αCD8 mAb (PBS/αCD8) alone or in combination (DT/αCD8; Figure 5A).